Prognostic Significance of Hypoalbuminemia in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (R/R-HL) Undergoing Salvage Autologous Bone Marrow/Peripheral Stem Cell Transplantation (auto-BM/PSCT).

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 5204-5204
Author(s):  
Kiarash Kojouri ◽  
Christian El-Khoury ◽  
Shubham Pant ◽  
Nancy Kohrt ◽  
George B. Selby ◽  
...  
Keyword(s):  
Overall Survival ◽  
Serum Albumin ◽  
Serum Albumin Level ◽  
Statistical Significance ◽  
Prognostic Significance ◽  
Albumin Level ◽  
Control Group ◽  
Survival Curves ◽  
The Difference

Abstract Background: Management of R/R-HL has been disappointing with salvage chemotherapy alone. Although controversy remains over the best time to perform a transplant, auto-BM/PSCT is considered an acceptable salvage therapeutic option for patients (pts) with R/R-HL. Hypoalbuminemia is one of the seven adverse prognostic factors for newly diagnosed pts with HL who receive chemotherapy according to the international prognostic factors project on advanced HL. The prognostic significance of hypoalbuminemia in pts with R/R-HL undergoing salvage auto-BM/PSCT is less clearly defined at the present time. Objective: To evaluate the prognostic significance of hypoalbuminemia in pts with R/R-HL who undergo salvage auto-BM/PSCT. Methods: A retrospective, single-institution study of consecutive pts with R/R-HL who received auto-BM/PSCT at the University of Oklahoma over the last 19 years (1985– 2004) was performed. The serum albumin level during hospital admission for transplant that was closest to, but before, high-dose chemotherapy was recorded and used for this analysis. Hypoalbuminemia was defined as a serum albumin level < 3.5 g/dl. Overall survival (OS) was defined as the time period in months from the day of transplant until death, or the last day of follow-up. Survival curves were estimated according to the Kaplan-Meier method, and were compared between the two groups (control group [≥3.5 g/dl] and low albumin group [< 3.5 g/dl]) with the use of the log-rank test. Median survivals of the two groups were also compared by using Wilcoxon-Mann-Whitney test. One-sided P-value of < 0.05 was considered statistically significant. SAS® sofware (version 8.0; Carry, NC) was used for statistical analysis. Results: 66 patients (40 males, 26 females) were identified, who were 13–69 years old (median 29 years) at the time of transplant. 40 pts (61%) died during follow-up, 4 pts (6%) were lost to follow-up at 15, 27, 58 and 103 months after transplant, and 22 pts (33%) are alive at the time of this analysis (7/30/04), 2–187 months (median 68 months) after transplant. Median survival for the control group (n1=27, 13/27 died) was 78 months (95% CI: 23 - N/A months) and for the low-albumin group (n2=39, 27/39 died) was 22 months (95% CI: 13– 44 months). The difference between overall survival curves (figure) and also the difference between median survivals approached, but did not reach statistical significance (p-values for log-rank and Wilcoxon-Mann-Whitney tests, 0.0632 and 0.0565, respectively). Conclusion: Our results suggest a trend for a worse outcome among pts who undergo salvage auto-BM/PSCT for R/R-HL with low serum albumin (<3.5 g/dl) before transplant. The lack of statistical significance in this analysis is likely related to the relatively limited sample size and the retrospective nature of the study. A larger, prospective analysis evaluating the potential adverse prognostic value of hypoalbuminemia in pts with R/R-HL undergoing auto-BM/PSCT is warranted. Figure Figure

scholarly journals Predictive Value of the Serum Albumin Level on Admission in Patients With Spontaneous Subarachnoid Hemorrhage

2021 ◽  
Vol 8 ◽  
Author(s):  
Feng Shang ◽  
Hao Zhao ◽  
Weitao Cheng ◽  
Meng Qi ◽  
Ning Wang ◽  
...  
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Serum Albumin ◽  
Serum Albumin Level ◽  
Length Of Hospital Stay ◽  
Albumin Level ◽  
Control Group ◽  
Number Of Patients ◽  
Poor Outcomes ◽  
Spontaneous Subarachnoid Hemorrhage

Objective: To determine the effect of the serum albumin level on admission in patients with spontaneous subarachnoid hemorrhage (SAH).Methods: A total of 229 patients with SAH were divided into control and hypoalbuminemia groups. The serum albumin levels were measured. The data, including age, gender, co-existing medical conditions, risk factors, Hunt-Hess (H-H) grade on admission, Glasgow coma score (GCS) on admission, complications during hospitalizations, length of hospital stay, length of intensive care unit (ICU) stay, in-hospital mortality, survival rate, outcome at discharge, and the 6-month follow-up outcome, were compared between the two groups.Results: Older age, an increased number of patients who consumed an excess of alcohol, and a lower GCS on admission were findings in the hypoalbuminemia group compared to the control group (p &lt; 0.001). The ratio of patients with H-H grade I on admission in the hypoalbuminemia group was decreased compared to the control group (p &lt; 0.05). Patients with hypoalbuminemia were more likely to be intubated, and have pneumonia and cerebral vasospasm than patients with a normal albumin level on admission (p &lt; 0.001). Furthermore, the length of hospital and ICU stays were longer in the hypoalbuminemia group than the control group (p &lt; 0.001). Hypoalbuminemia on admission significantly increased poor outcomes at discharge (p &lt; 0.001). The number of patients with severe disability was increased and the recovery rate was decreased with respect to in-hospital outcomes in the hypoalbuminemia group than the control group (p &lt; 0.001).Conclusion: Hypoalbuminemia was shown to be associated with a poor prognosis in patients with SAH.

Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs.

1991 ◽  
Vol 9 (2) ◽  
pp. 211-219 ◽  
Author(s):  
B Coiffier ◽  
C Gisselbrecht ◽  
J M Vose ◽  
H Tilly ◽  
R Herbrecht ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Serum Albumin ◽  
Serum Albumin Level ◽  
Bone Marrow Involvement ◽  
Prognostic Index ◽  
Albumin Level ◽  
Advanced Stage ◽  
Low Serum

The objectives of this study were to determine prognostic factors for response to treatment, freedom-from-relapse (FFR) survival, and overall survival of 737 aggressive malignant lymphoma patients treated with the doxorubicin, cyclophosphamide, vindesine, bleomycin, methylprednisolone, methotrexate with leucovorin, ifosfamide, etoposide, asparaginase, and cytarabine (LNH-84) regimen; to construct a prognostic index with factors isolated by multivariate analyses; and to validate this prognostic index with another set of patients. Complete response (CR) was reached in 75% of LNH-84 patients, and 30% of them relapsed. With a median follow-up of 36 months, median FFR survival and median overall survival were not reached. Low serum albumin level, high tumoral mass, weight loss, bone marrow involvement, greater than or equal to 2 extranodal sites, and increased lactic dehydrogenase (LDH) level were associated with a low response rate. Advanced stage, increased LDH level, and nonlarge-cell histologic subtypes (diffuse mixed, lymphoblastic, and small non-cleaved) were statistically associated with a high relapse rate and short FFR survival. Increased LDH level, low serum albumin level, tumoral mass larger than 10 cm, greater than or equal to 2 extranodal sites, advanced stage, and age older than 65 years were statistically associated with short overall survival. Four of these parameters, namely, LDH level, stage, number of extranodal sites, and tumoral mass, were put together to construct a prognostic index. This index partitioned LNH-84 patients into three subgroups of good, intermediate, and poor prognosis (P less than .00001): CR rates of 93%, 83%, and 61%; relapse rates of 12%, 25%, and 45%; 3-year FFR survival of 87%, 73%, and 53%, and 3-year survival of 88%, 71%, and 41%, respectively. This prognostic index was applied to a test set of patients: 155 patients treated on protocols of the Nebraska Lymphoma Study Group. Using this index, these patients had 3-year FFR survival of 70%, 40%, and 22% (P = .0002) and 3-year survival of 79%, 52%, and 31% (P = .005). In patients with aggressive lymphomas, this simple prognostic index could distinguish between patients requiring intensive treatment such as autologous bone marrow transplantation in first complete remission and those who could be treated with standard regimens.

scholarly journals The prognostic significance of preoperative serum albumin in urothelial carcinoma: a systematic review and meta-analysis

2018 ◽  
Vol 38 (4) ◽  
Author(s):  
Jing Liu ◽  
Fang Wang ◽  
Shaohong Li ◽  
Wenhui Huang ◽  
Yanjuan Jia ◽  
...  
Keyword(s):  
Serum Albumin ◽  
Urothelial Carcinoma ◽  
Serum Albumin Level ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Albumin Level ◽  
Cochrane Library ◽  
Tumor Type ◽  
Poor Overall Survival ◽  
Preoperative Serum

Preoperative serum albumin has been considered to be closely correlated with the prognosis of various cancers, including urothelial carcinoma (UC). However, to date, this conclusion remains controversial. The aim of this meta-analysis is to investigate the prognostic significance of preoperative serum albumin in UC. A literature search was performed in PubMed, Web of Science, Embase, and Cochrane Library up to 4 July 2017. Herein, a total of 15506 patients from 23 studies were enrolled in our meta-analysis. Decreased preoperative serum albumin level predicted poor overall survival (OS) (HR = 1.88, 95% CI: 1.44–2.45, P<0.0001), cancer-specific survival (CSS) (HR = 2.03, 95% CI: 1.42–2.90, P=0.0001), recurrence-free survival (HR = 1.85, 95% CI: 1.15–2.97, P=0.01), 30-day complications (30dCs) after surgery (odds ratio (OR) = 1.93, 95% CI: 1.16–3.20, P=0.01), and 90-day mortality after surgery (OR = 4.24, 95% CI: 2.20–8.16, P<0.001). The subgroup analyses indicated that low preoperative serum albumin level is still positively associated with a worse prognosis of UC based on ethnicity, cut-off value, tumor type, analyses type, and sample size. Our meta-analysis indicated that reduced preoperative serum albumin level was a predictor of poor prognosis of UC.

P0411PREDICTORS OF RENAL AND PATIENT OUTCOME IN PATIENTS WITH IDIOPATHIC MEMBRANOUS NEPHROPATHY: FROM KOGNET DATA

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Ji-Young Choi ◽  
Ji Hye Kim ◽  
Ga Young Lee ◽  
Hee Won Noh ◽  
Soojee Jeon ◽  
...  
Keyword(s):  
Risk Factors ◽  
Patient Outcome ◽  
Serum Albumin ◽  
Serum Albumin Level ◽  
Patient Survival ◽  
Albumin Level ◽  
Proportional Hazard ◽  
Cox Proportional Hazard ◽  
Cox Proportional Hazard Regression

Abstract Background and Aims Idiopathic membranous nephropathy (iMN) is a leading cause of nephrotic syndrome and one of the major causes of end-stage renal disease (ESRD). Various factors can affect renal and patient outcome in patients with iMN. In this study, we analyzed the predictors of renal and patient survival in patients with iMN. Method We analyzed 1,776 patients diagnosed with iMN in Korean GlomeruloNEphritis STudy (KoGNET), a retrospective database of patients with renal biopsy from 1979 to 2018 from 18 centers in Korea. Student t-test for continuous variables and Chi-square test for categorical variables were performed for analyses. Cox proportional hazard regression was used to determine risk factors affecting renal and patient survival. Results The mean age of patients was 53.0 ± 14.7 years old and 1,075 (60.5%) were male. At the time of renal biopsy, 755 (46.0%) and 266 (16.2%) had hypertension and diabetes, respectively. Serum albumin level was 2.7 ± 0.8 g/dL and 871 (49.0%) had nephrotic range of proteinuria. When analyzed by dividing over 65 and under, the hemoglobin and serum albumin level were lower, more patients showed nephrotic ranged proteinuria, and higher prevalence of comorbidities such as hypertension, diabetes, coronary heart disease and cerebrovascular disease in the group over 65 than in the group under 65. Median duration of follow-up was 88.0 (38.0 – 115.1) months. Complete or partial remission rates were 48.5%, 63.8%, and 68.0% at 6 months, 12months after biopsy, and last follow-up, respectively. In Cox proportional hazard regression, high hemoglobin [HR 0.66 (0.47 – 0.93), p=0.017], high serum albumin level [HR 0.41 (0.18 – 0.94), p=0.034], and high estimated GFR by CKD-EPI equation [HR 0.94 (0.91 – 0.96), p&lt;0.001] at biopsy were good predictors for renal outcome, whereas presence of cerebrovascular disease at biopsy [HR 6.45 (1.16 – 35.71), p=0.033] were poor prognostic factors for ESRD. Age 65 and older [HR 3.26 (1.53 – 6.95), p=0.002] and presence of hypertension at biopsy [HR 2.45 (1.09 – 5.54), p=0.031] were significant risk factors for patient survival in multivariate Cox proportional regression analysis. Conclusion High hemoglobin and serum albumin, and good renal function at biopsy were good predictors for renal survival. Older age and hypertension at biopsy were poor prognostic factors for patient survival in iMN patients. Prognostic information of outcomes in this study might be helpful to optimize management in iMN patients.

A low albumin to globulin ratio with a high serum globulin level is a prognostic marker for poor survival in cervical cancer patients treated with radiation based therapy

2019 ◽  
Vol 29 (1) ◽  
pp. 17-22 ◽  
Author(s):  
Yasunori Yoshino ◽  
Ayumi Taguchi ◽  
Takuya Shimizuguchi ◽  
Yujiro Nakajima ◽  
Maki Takao ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Overall Survival ◽  
Serum Albumin ◽  
Cancer Patients ◽  
Serum Albumin Level ◽  
Albumin Level ◽  
High Serum ◽  
Serum Globulin ◽  
Globulin Level ◽  
Albumin To Globulin Ratio

ObjectiveWe investigated whether the pretreatment albumin to globulin ratio, serum albumin level, and serum globulin level can be used to predict survival among cervical cancer patients treated with radiation based therapy and assessed globulin fractions.MethodsWe retrospectively enrolled 128 patients with cervical cancer treated with radiation based therapy at our institution between 2010 and 2015. The associations of the pretreatment albumin to globulin ratio, and serum albumin and globulin levels with overall survival were assessed. Additionally, the associations of the globulin fractions with the serum globulin levels and overall survival were evaluated.ResultsMedian follow-up duration was 30 months (IQR 16–44 months). A low albumin to globulin ratio (< 1.53) was found to be an independent prognostic factor for overall survival (HR= 3.07; 95% CI, 1.03 to 13.3; P=0.044). On evaluating serum globulin and albumin separately, a high serum globulin level was significantly associated with overall survival (cut-off value 2.9 g/dL; HR=3.74; 95% CI 1.08 to 23.6; P=0.036) whereas a low serum albumin level was not associated with overall survival (cut-off value 3.6 g/dL; HR=1.77; 95% CI 0.57 to 4.54; P=0.29). Electrophoresis data of the serum proteins revealed that the γ-globulin fraction was most strongly correlated with the globulin levels (P<0.001). Furthermore, a high γ-globulin level (≥1.28 g/dL) was significantly associated with poor overall survival (log rank test, P=0.034).ConclusionsA pretreatment low albumin to globulin ratio, which might be attributable to a high serum globulin level, can be used to predict poor prognosis in cervical cancer patients treated with radiation based therapy.

The impact of modified Glasgow prognostic score on survival in patients with gastric cancer.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 104-104
Author(s):  
Hironobu Goto ◽  
Masanori Tokunaga ◽  
Rie Makuuchi ◽  
Yutaka Tanizawa ◽  
Etsuro Bando ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Serum Albumin ◽  
Serum Albumin Level ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Infectious Complications ◽  
Albumin Level ◽  
Modified Glasgow Prognostic Score ◽  
Serum Crp

104 Background: Modified Glasgow Prognostic Score (mGPS), based on serum C-reactive protein (CRP) and albumin-levels, was reported to be a good prognosticator for survival in patients with lung cancer. However, the role of mGPS in gastric cancer is still controversial. The aim of this study is to clarify the significance of mGPS as a prognosticator in patients with gastric cancer. Methods: This study included 1,062 patients who underwent gastrectomy for gastric cancer at Shizuoka Cancer Center between September 2002 and December 2006. Patients who received neoadjuvant chemotherapy, and those who had other cancers were excluded from the analysis. mGPS is defined by serum CRP level and serum albumin level. Patients with serum CRP level of 1.0mg/dl or lower were classified to mGPS 0 irrespective to the serum albumin level. Patients with elevated serum CRP level (>1.0mg/dl) were classified to mGPS1 or mGPS2 according to the serum albumin level (mGPS1, albumin≥3.5g/dl; mGPS2, albumin<3.5g/dl). We compared relationships between mGPS and clinicopathological characteristics of patients, the incidence of intra-abdominal infectious complications (Clavien-Dindo grade II or more severe), and overall survival. Results: There were 712 male and 350 female patients. The median age was 65 years old. The number of patients classified to the mGPS0, mGPS1, and mGPS2 group were 970 (91.3%), 59 (5.6%), and 33 (3.1%), respectively. The incidences of intra-abdominal infectious complications were 27.1% in mGPS1, and 24.3% in mGPS2, and were significantly higher than that in mGPS0 (9.5%, P< 0.001). Overall five-year survival rates were 74.6% in mGPS0, 61.4% in mGPS1, and 34.6% in mGPS2. The overall survival was significantly worse in patients with mGPS2 than those with mGPS0 or mGPS1 (P<0.001). Conclusions: mGPS was correlated with the incidence of intra-abdominal infectious complications. In addition, mGPS was found to be a prognosticator for survival in patients with gastric cancer. Preoperative nutritional support may lead to reduced incidence of surgical complications and improved survival outcome after gastrectomy in patients with gastric cancer.

Albumin Is a Prognostic Factor for Overall Survival in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML)

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4253-4253
Author(s):  
Awais M. Khan ◽  
Jeffrey E. Lancet ◽  
Mohamed A. Kharfan-Dabaja ◽  
Najla H Al Ali ◽  
Alan F. List ◽  
...  
Keyword(s):  
Overall Survival ◽  
Serum Albumin ◽  
Induction Chemotherapy ◽  
Serum Albumin Level ◽  
Cox Regression ◽  
Albumin Level ◽  
Normal Serum ◽  
Newly Diagnosed ◽  
Kaplan Meier ◽  
History Of

Abstract Abstract 4253 Background: Hypoalbuminemia (HA) is a strong predictor of poor clinical outcomes in many medical conditions. Low serum albumin is recognized as an adverse prognostic factor in patients with neoplastic diseases such as multiple myeloma, melanoma, and colon cancer. Severe hypoalbuminemia (<3.0 g/dl) at day +90 post allogeneic hematopoietic cell transplant (AHCT) was reported as an independent predictive variable for non-relapse mortality and overall survival (Kharfan-Dabaja, et al Biol Blood Marrow Transplant 2009; 15). A separate study conducted by our group showed that in patients with relapsed and refractory AML, serum albumin < 3.5 g/dl prior to salvage chemotherapy, correlated with lower complete remission (CR) rate and inferior overall survival (OS) (Komrokji, et al ASH 2009). We examined the prognostic value of serum albumin level prior to induction chemotherapy in patients with newly diagnosed AML. Methods: Data were collected retrospectively in a cohort of newly diagnosed AML patients who received induction chemotherapy (3+ 7 regimen). The primary objective of this study is to examine the relationship between serum albumin at baseline and probability for achieving complete remission (CR) or incomplete remission (CRi) and overall survival (OS). All analyses were conducted using SPSS version 19.0. The Kaplan–Meier method was used to estimate median overall survival; chi-square test was used for comparison of categorical variables and t-test for continuous variables. Log rank test was used to compare Kaplan–Meier survival estimates between two groups and Cox regression for multivariable analysis. Results: Between November 2004 and July 2007, 135 patients who received 3+7 induction chemotherapy at Moffitt Cancer Center were included in this analysis. Patient baseline characteristics were similar between patients with baseline serum albumin < 3.5 g/dl (HA) and those with serum albumin ≥ 3.5 g/dl (no HA) with respect to age, sex, FAB subtype, history of antecedent MDS, karyotype, and chemotherapy. Patients with HA, mean age was 60 years compared to 56.5 years in non HA group. The median OS for patients with HA was 221 days (95%CI 149.5–292.5) compared to 421 days (95%CI 236.7–605) with normal serum albumin (p<0.005). (Figure-1) The CR/CRi rate was 64%% for HA and 77.6% for those with normal albumin (p=0.09). In a multivariable Cox regression analysis including age ≥ 60 years, history of MDS, karyotype, and serum albumin level at baseline; only age, karyotype and serum albumin were independent predictors of OS [Hazard ratio 0.47 (95%CI 0.31–0.71) (p<0.005) for normal serum albumin group]. Conclusion: In this cohort of patients with newly diagnosed AML, we demonstrate that hypoalbuminemia < 3.5 g/dl is an independent covariate for overall survival with conventional chemotherapy management. Serum albumin is a surrogate marker of general health, comorbidities, and performance status. The prognostic value of low serum albumin should be validated in a prospective study. Disclosures: No relevant conflicts of interest to declare.

Study of the clinical significance of serum albumin level in Preeclampsia and in the detection of its severity

2016 ◽  
Vol 4 (1) ◽  
pp. 110-120
Author(s):  
Basima Al Ghazali ◽  
Ahlam Al-Taie
Keyword(s):  
Serum Albumin ◽  
Serum Albumin Level ◽  
Gestational Hypertension ◽  
Albumin Level ◽  
Maternal Serum ◽  
Control Group ◽  
Perinatal Morbidity ◽  
Plasma Albumin ◽  
Mild Preeclampsia ◽  
And Control

Pre-eclampsia is a form of severe disorder of pregnancy, leading to maternal and perinatal morbidity and mortality. Many biochemical markers of preeclampsia have been recognized in maternal serum one of them is serum albumin. The objective of this study is to determine whether plasma albumin level (ALB) is associated with preeclampsia (PE) complications and to evaluate the usefulness of its level as a marker of preeclampsia severity. The studied group were collected in the labour word. First group were normotensive as a control group, the second group with a gestational hypertension, the third group were mild preeclampsia and fourth group had sever preeclampsia. A comparison of the characteristic of each group and the correlation between serum albumin levels and gestational age at time of delivery, pregnancy complications and outcome were statistically analyzed. The results are showed that serum albumin level had statistically significant decline at (P≤0.01) in severe preeclampsia with mean level (2.618-0.328) than in mild preeclampsia (3.155-0.293) in comparison to hypertensive and control group (3.500-0.386), (4.076-1.448) respectively so there is positive correlation between serum albumin levels and severity of disease. We are concluded that serum albumin level in pre-eclampsia can be used as a significant determinant of disease severity and may be used as a useful marker for predicting time of delivery or termination of pregnancy and pregnancy outcomes.

Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6586-6586
Author(s):  
Awais M. Khan ◽  
Jeffrey E. Lancet ◽  
Mohamed A. Kharfan-Dabaja ◽  
Najla Al Ali ◽  
Alan F. List ◽  
...  
Keyword(s):  
Overall Survival ◽  
Serum Albumin ◽  
Induction Chemotherapy ◽  
Prognostic Value ◽  
Serum Albumin Level ◽  
Albumin Level ◽  
Normal Serum ◽  
Newly Diagnosed ◽  
Kaplan Meier ◽  
History Of

6586 Background: Hypoalbuminemia (HA) is an adverse prognostic factor in multiple neoplastic diseases. Severe hypoalbuminemia (<3.0 g/dl) at day +90 post allogeneic hematopoietic cell transplant (AHCT) was reported as an independent predictive variable for non-relapse mortality and overall survival (Kharfan-Dabaja, et al Biol Blood Marrow Transplant 2009; 15). We examined the prognostic value of serum albumin level prior to induction chemotherapy in patients with newly diagnosed AML. Methods: Data were collected retrospectively in newly diagnosed AML patients receiving induction chemotherapy (3+ 7 regimen). Primary objective was to examine the relationship between serum albumin at baseline and probability of achieving complete remission (CR) or incomplete remission (CRi) and overall survival (OS). The Kaplan–Meier method used to estimate median overall survival; chi-square test used for comparison of categorical variables and t-test for continuous variables. Log rank test used to compare Kaplan–Meier survival estimates between two groups. Results: Between November 2004 to July 2007, 135 patients who received 3+7 induction chemotherapy were included. Patient baseline characteristics were similar between patients with serum albumin < 3.5 g/dl (HA) and those with serum albumin ≥ 3.5 g/dl (no HA) with respect to age, sex, FAB subtype, history of antecedent MDS, karyotype, and chemotherapy . In patients with HA, mean age was 60 years compared to 56.5 years in non HA group. The median OS for patients with HA was 221 days (95%CI 149.5-292.5) compared to 421 days (95%CI 236.7-605) with normal serum albumin (p<0.005). (Figure-1) The CR/CRi rate was 64%% for HA and 77.6% for those with normal albumin (p=0.09). In a multivariable Cox regression analysis including age ≥ 60 years, history of MDS, karyotype, and serum albumin level at baseline; only age, karyotype and serum albumin were independent predictors of OS [Hazard ratio 0.47 (95%CI 0.31-0.71) (p<0.005) for normal serum albumin group]. Conclusions: In newly diagnosed AML, we demonstrate that hypoalbuminemia < 3.5 g/dl is an independent covariate for overall survival with conventional chemotherapy management. The prognostic value of low serum albumin should be validated in a prospective study.

scholarly journals Serum Albumin Levels in Severe Traumatic Brain Injury: Role as a Predictor of Outcome

2020 ◽  
Vol 17 (01) ◽  
pp. 24-27
Author(s):  
Raghavendra Nayak ◽  
Nitin Jagdhane ◽  
Sanjeev Attry ◽  
Samarendranath Ghosh
Keyword(s):  
Traumatic Brain Injury ◽  
Serum Albumin ◽  
Severe Head Injury ◽  
Serum Albumin Level ◽  
Albumin Level ◽  
Normal Serum ◽  
Severe Tbi ◽  
The Mean ◽  
Low Serum

Abstract Background Serum albumin has long been considered as an outcome marker in various critical illnesses. The aim of our study is to ascertain the role of serum albumin as a predictor of outcome in severe head injury patients. Materials and Methods This is a prospective observational study of patients with severe traumatic brain injury (TBI). Depending on the serum albumin level at admission, patients were dichotomized into two groups: one with normal serum albumin and other with hypoalbuminemia. Their outcomes at 6-month follow-up were assessed by the modified Glasgow Outcome Score. Result Eighty patients (57 males and 23 females) with severe TBI were included in the study. The mean age of the study patients was 39.6 + 13.1 years and the mean serum albumin level at admission was 3.7 + 1.2 g/dL with lowest being 2.2 mmol/L and highest being 6.1 mmol/L. Thirty-four patients (42.5%) had low serum albumin level (< 3.5 g/dL) at admission. At 6-month follow-up, 58 (72.5%) patients had a good neurological outcome and 22 (27.5%) had a poor outcome. The group with normal serum albumin levels showed a significantly better outcome compared with the hypoalbuminemia group (p = 0.01). On multiple regression analysis, low serum albumin emerged as the only predictor of the poor outcome in severe head injury patients. Conclusion Serum albumin at admission is an independent predictor of outcome in severe TBI patients. Larger prospective studies are required to confirm these findings.

Sign in / Sign up

Export Citation Format

Share Document